SCHEDULE: BridgeBio Oncology Therapeutics: Stakeholder Share Distribution

BridgeBio Oncology Therapeutics, Inc. reports a pro rata distribution of shares by Helix Holdings II LLC to its members, impacting ownership percentages.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of BridgeBio Oncology Therapeutics, Inc. common stock.
• Helix Holdings II LLC (Sponsor) distributed 4,528,186 shares of common stock pro rata to its members on July 1, 2026.
• Following the distribution, Sponsor holds no shares of common stock.
• Cormorant Private Healthcare Fund III, LP acquired 2,692,459 shares, Cormorant Private Healthcare Fund V, LP acquired 1,704,862 shares, and Cormorant Global Healthcare Master Fund, LP acquired 130,865 shares as a result of this distribution.
• Bihua Chen, as managing member of various Cormorant entities and manager of Sponsor, has voting and investment discretion over these shares.
• The reporting persons have entered into a joinder to a lock-up agreement, agreeing to be bound by transfer restrictions on the distributed shares.
• Bihua Chen was also granted 31,675 unvested stock options on June 16, 2026, as consideration for her director services.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing administrative changes in share ownership and compliance with existing agreements, without providing new financial performance or strategic information.

Positives

• The pro rata distribution of shares by Sponsor to its members allows for a clearer and more direct ownership structure.
• The acquisition of shares by Cormorant funds increases their direct holdings, potentially aligning incentives.
• Bihua Chen's stock options grant indicates continued engagement and potential future value realization for her services as a director.

Negatives

• The filing does not contain financial performance data, making it difficult to assess the company's operational health.
• The distribution of shares by Sponsor results in the Sponsor entity itself holding no shares, which could be perceived as a divestment from that specific entity's direct holdings.

Risks

• The lock-up agreement imposes transfer restrictions on the distributed shares, limiting the immediate liquidity for the recipient funds.
• The reliance on Bihua Chen for managing member and director roles, coupled with her stock options, could present governance considerations if not managed appropriately.

Future Outlook

The filing primarily concerns changes in share ownership and adherence to existing agreements, rather than providing forward-looking financial guidance or strategic outlook for BridgeBio Oncology Therapeutics, Inc.

Management Comments

• Bihua Chen, as managing member of various entities and manager of Sponsor, has voting and investment discretion with respect to the shares held by each of the Cormorant Funds.
• Ms. Chen disclaims any beneficial ownership of the securities held by the each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice of fund restructuring and direct share allocation to underlying investment vehicles, often to streamline reporting and management of holdings. The adherence to lock-up agreements is standard for significant shareholders in publicly traded companies, especially in the biotechnology sector where such arrangements are prevalent.

Management Changes

Corporate Governance

Related Party Transactions

• Distribution of 4,528,186 shares of Common Stock from Helix Holdings II LLC (Sponsor) to its members (Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Global Healthcare Master Fund, LP) on July 1, 2026.

Stakeholder Impact

• Shareholders: The distribution and subsequent adherence to the lock-up agreement by the Cormorant funds may influence trading dynamics and share availability in the short to medium term.
• Management: Bihua Chen's role as a director and her stock options grant highlight her continued involvement and potential financial stake in the company's performance.
• Investment Funds (Cormorant entities): Direct ownership of shares provides greater control and transparency over their investment in BridgeBio Oncology Therapeutics, Inc.

Next Steps

• The reporting persons will continue to be bound by the terms of the Lock-Up Agreement with respect to the distributed shares.
• Bihua Chen's stock options will vest according to the specified schedule, subject to continued service.

Key Dates

Keywords

Schedule 13D, BridgeBio Oncology Therapeutics, Cormorant Asset Management, Bihua Chen, Share Distribution, Beneficial Ownership, Lock-Up Agreement, Stock Options, SEC Filing